Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
10 05 2021
Historique:
received: 27 02 2021
accepted: 19 04 2021
entrez: 11 5 2021
pubmed: 12 5 2021
medline: 26 10 2021
Statut: epublish

Résumé

Dickkopf-1 (DKK1) is a secreted modulator of Wnt signaling that is frequently overexpressed in tumors and associated with poor clinical outcomes. DKN-01 is a humanized monoclonal therapeutic antibody that binds DKK1 with high affinity and has demonstrated clinical activity in gastric/gastroesophageal junction (G/GEJ) patients with elevated tumoral expression of DKK1. Here we report on the validation of a DKK1 RNAscope chromogenic in situ hybridization assay to assess DKK1 expression in G/GEJ tumor tissue. To reduce pathologist time, potential pathologist variability from manual scoring and support pathologist decision making, a digital image analysis algorithm that identifies tumor cells and quantifies the DKK1 signal was developed. Following CLIA guidelines the DKK1 RNAscope chromogenic in situ hybridization assay and digital image analysis algorithm were successfully validated for sensitivity, specificity, accuracy, and precision. The DKK1 RNAscope assay in conjunction with the digital image analysis solution is acceptable for prospective screening of G/GEJ adenocarcinoma patients. The work described here will further advance the companion diagnostic development of our DKK1 RNAscope assay and could generally be used as a guide for the validation of RNAscope assays with digital image quantification.

Identifiants

pubmed: 33972574
doi: 10.1038/s41598-021-89060-3
pii: 10.1038/s41598-021-89060-3
pmc: PMC8110580
doi:

Substances chimiques

Biomarkers, Tumor 0
DKK1 protein, human 0
Intercellular Signaling Peptides and Proteins 0
RNA, Messenger 0

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

9920

Références

Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Cancer Res. 2010 Dec 1;70(23):9916-26
pubmed: 21098705
Dev Cell. 2009 Jul;17(1):9-26
pubmed: 19619488
Cell. 2016 Mar 24;165(1):45-60
pubmed: 27015306
J Mol Diagn. 2012 Jan;14(1):22-9
pubmed: 22166544
Development. 2018 Jun 8;145(11):
pubmed: 29884654
Mod Pathol. 2016 Apr;29(4):318-29
pubmed: 26916072
Adv Anat Pathol. 2015 Nov;22(6):384-7
pubmed: 26452213
J Clin Invest. 2016 Jul 1;126(7):2689-705
pubmed: 27322059
Dig Liver Dis. 2013 Mar;45(3):251-7
pubmed: 23266194
Mod Pathol. 2018 Apr;31(4):623-632
pubmed: 29271413
Curr Biol. 2001 Jun 26;11(12):951-61
pubmed: 11448771
Clin Cancer Res. 2020 Dec 1;26(23):6158-6167
pubmed: 32878766
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Blood. 2009 Jul 9;114(2):371-9
pubmed: 19417213
Nat Rev Cancer. 2013 Jan;13(1):11-26
pubmed: 23258168
PLoS One. 2019 Apr 15;14(4):e0215393
pubmed: 30986253
Arch Pathol Lab Med. 2017 Sep;141(9):1267-1275
pubmed: 28557614
Expert Opin Investig Drugs. 2020 Jul;29(7):639-644
pubmed: 32408777
Cancer Res. 2010 Jul 1;70(13):5326-36
pubmed: 20551066
Mol Cancer Res. 2021 Apr;19(4):717-725
pubmed: 33443105
Br J Pharmacol. 2017 Dec;174(24):4637-4650
pubmed: 28574171
Nature. 1998 Jan 22;391(6665):357-62
pubmed: 9450748
Cell. 2012 Jun 8;149(6):1192-205
pubmed: 22682243
Lancet Oncol. 2019 Oct;20(10):1454-1466
pubmed: 31405822
Methods Mol Biol. 2014;1211:201-12
pubmed: 25218387
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Oncotarget. 2016 Apr 19;7(16):21114-23
pubmed: 27049730
Bone. 2013 Apr;53(2):487-96
pubmed: 23333523
J Exp Med. 2016 May 2;213(5):827-40
pubmed: 27045006
Cell Death Dis. 2014 Feb 27;5:e1093
pubmed: 24577091
Appl Immunohistochem Mol Morphol. 2020 May/Jun;28(5):347-353
pubmed: 30920963
JCO Precis Oncol. 2020 Sep 29;4:
pubmed: 33015525
Pathol Res Pract. 2018 Dec;214(12):2087-2092
pubmed: 30377025
Am J Surg Pathol. 2018 Dec;42(12):1636-1646
pubmed: 30312179
Hum Pathol. 2016 Jan;47(1):95-103
pubmed: 26518664
Gynecol Oncol. 2020 Jun;157(3):765-774
pubmed: 32192732

Auteurs

Charles Caldwell (C)

Flagship Biosciences, Westminster, CO, USA.

James B Rottman (JB)

Athenaeum Pathology Consulting, Sudbury, MA, USA.

Will Paces (W)

Flagship Biosciences, Westminster, CO, USA.

Elizabeth Bueche (E)

Flagship Biosciences, Westminster, CO, USA.

Sofia Reitsma (S)

Flagship Biosciences, Westminster, CO, USA.

Joseph Gibb (J)

Flagship Biosciences, Westminster, CO, USA.

Vitria Adisetiyo (V)

Flagship Biosciences, Westminster, CO, USA.

Michael S Haas (MS)

Leap Therapeutics Inc., 47 Thorndike Street, Suite B1-1, Cambridge, MA, 02141, USA.

Heidi Heath (H)

Leap Therapeutics Inc., 47 Thorndike Street, Suite B1-1, Cambridge, MA, 02141, USA.

Walter Newman (W)

Leap Therapeutics Inc., 47 Thorndike Street, Suite B1-1, Cambridge, MA, 02141, USA.

Jason Baum (J)

Leap Therapeutics Inc., 47 Thorndike Street, Suite B1-1, Cambridge, MA, 02141, USA.

Roberto Gianani (R)

Flagship Biosciences, Westminster, CO, USA.

Michael H Kagey (MH)

Leap Therapeutics Inc., 47 Thorndike Street, Suite B1-1, Cambridge, MA, 02141, USA. mkagey@leaptx.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH